FDA-cleared profile

HealthICH

Zebra Medical Vision Ltd. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Case-level triage of adult non-contrast head CT examinations with features suggestive of intracranial hemorrhage (ICH); not a diagnostic or rule-out tool.

Clinical role
Parallel case-level triage and notification support; standard-of-care review remains required and cases are not removed from the worklist.
Images and patients
CT/CTA · Head/brain
Key limitation
Keep in mind: Indicated only for adults and suspected ICH on non-contrast head CT. It does not address anomalies other than ICH, direct attention to an image location, make standalone clinical decisions, rule out hemorrhage, or preclude clinical assessment.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Case-level triage of adult non-contrast head CT examinations with features suggestive of intracranial hemorrhage (ICH); not a diagnostic or rule-out tool.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Head/brain Input: DICOM adult non-contrast head CT studies; input validation checks age, modality, and view compatibility.
  • Who uses it?Intended users: Radiologists and other qualified medical staff who regularly read head CT scans
  • What does the software produce?Output: A case-level suspected-ICH notification is sent through the Zebra Imaging Analytics Platform to a PACS/workstation for worklist prioritization; no image, marking, or highlighted location is output.
  • What is its most important limitation?Key limitation: Indicated only for adults and suspected ICH on non-contrast head CT. It does not address anomalies other than ICH, direct attention to an image location, make standalone clinical decisions, rule out hemorrhage, or preclude clinical assessment.

Clinical takeaway. Clinical role: Case-level triage of adult non-contrast head CT examinations with features suggestive of intracranial hemorrhage (ICH); not a diagnostic or rule-out tool.

Evidence takeaway. Evidence from the reviewed source record: Retrospective stand-alone validation used 427 anonymized head CT cases from the USA and Israel (199 ICH-positive and 228 negative), ages 18-102, truthed by two US board-certified neuroradiologists with a third senior neuroradiologist for disagreement. FDA reported sensitivity 94.47% (95% CI: 90.32%-97.21%), specificity 92.54% (95% CI: 88.33%-95.60%), overall agreement 93% (95% CI: 90.66-95.60), and mean per-case processing time 48.67 seconds (95% CI: 47.06-50.28).

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Case-level triage of adult non-contrast head CT examinations with features suggestive of intracranial hemorrhage (ICH); not a diagnostic or rule-out tool.
  • Exact FDA submission
  • Checked 2026-09-09
Workflow role
Parallel case-level triage and notification support; standard-of-care review remains required and cases are not removed from the worklist.
  • Exact FDA submission
  • Checked 2026-09-09
Required input
DICOM adult non-contrast head CT studies; input validation checks age, modality, and view compatibility.
  • Exact FDA submission
  • Checked 2026-09-09
Output and clinician action
A case-level suspected-ICH notification is sent through the Zebra Imaging Analytics Platform to a PACS/workstation for worklist prioritization; no image, marking, or highlighted location is output.
  • Exact FDA submission
  • Checked 2026-09-09
Care setting
Medical care environment
  • Exact FDA submission
  • Checked 2026-09-09
Intended users
Radiologists and other qualified medical staff who regularly read head CT scans
  • Exact FDA submission
  • Checked 2026-09-09
Limitations
Indicated only for adults and suspected ICH on non-contrast head CT. It does not address anomalies other than ICH, direct attention to an image location, make standalone clinical decisions, rule out hemorrhage, or preclude clinical assessment.
  • Exact FDA submission
  • Checked 2026-09-09
Evidence summary
Retrospective stand-alone validation used 427 anonymized head CT cases from the USA and Israel (199 ICH-positive and 228 negative), ages 18-102, truthed by two US board-certified neuroradiologists with a third senior neuroradiologist for disagreement. FDA reported sensitivity 94.47% (95% CI: 90.32%-97.21%), specificity 92.54% (95% CI: 88.33%-95.60%), overall agreement 93% (95% CI: 90.66-95.60), and mean per-case processing time 48.67 seconds (95% CI: 47.06-50.28).
  • Exact FDA submission
  • Checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Retrospective stand-alone validation used 427 anonymized head CT cases from the USA and Israel (199 ICH-positive and 228 negative), ages 18-102, truthed by two US board-certified neuroradiologists with a third senior neuroradiologist for disagreement. FDA reported sensitivity 94.47% (95% CI: 90.32%-97.21%), specificity 92.54% (95% CI: 88.33%-95.60%), overall agreement 93% (95% CI: 90.66-95.60), and mean per-case processing time 48.67 seconds (95% CI: 47.06-50.28).
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Reported sensitivity
Standalone per-case sensitivity for suspected ICH versus truthed ground truth: 94.47% (95% CI: 90.32%-97.21%).
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09

FDA reports this endpoint for the 427-case retrospective head CT validation; it is not overall agreement or processing time.

Reported specificity
Standalone per-case specificity for suspected ICH versus truthed ground truth: 92.54% (95% CI: 88.33%-95.60%).
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09

FDA reports this endpoint separately from sensitivity, overall agreement, and the timing result.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

HealthICH regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K190424
  • Samplen=427
  • IndependenceIndependence not established

K190424

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K190424. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM adult non-contrast head CT studies; input validation checks age, modality, and view compatibility.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-09 · FDA K190424: HealthICH

  2. Routing

    Source context, not route validation: After a head CT, a copy of the study is automatically retrieved and processed; HealthICH returns the notification to the Zebra Imaging Analytics Platform, which distributes it to the PACS/workstation through the worklist interface. The packet identifies DICOM images but does not establish a specific local PACS interface.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-09 · FDA K190424: HealthICH

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 ·

  4. Returned objects

    Source context, not route validation: A case-level suspected-ICH notification is sent through the Zebra Imaging Analytics Platform to a PACS/workstation for worklist prioritization; no image, marking, or highlighted location is output.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-09 · FDA K190424: HealthICH

  5. Viewer/worklist/report

    Unresolved route: A case-level suspected-ICH notification is sent through the Zebra Imaging Analytics Platform to a PACS/workstation for worklist prioritization; no image, marking, or highlighted location is output.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-09 · FDA K190424: HealthICH

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
After a head CT, a copy of the study is automatically retrieved and processed; HealthICH returns the notification to the Zebra Imaging Analytics Platform, which distributes it to the PACS/workstation through the worklist interface. The packet identifies DICOM images but does not establish a specific local PACS interface.
  • Exact FDA submission
  • Checked 2026-09-09
Training
The 510(k) summary states HealthICH is intended for use by radiologists and other qualified medical staff who read head CT scans on a regular basis, and that the final diagnosis is provided by a radiologist or other qualified physician after examining the original scan as determined by the clinical standard of care.
  • Exact FDA submission
  • Checked 2026-10-27

User qualification wording only; the summary specifies no training program or training offering for this device.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Result destination

PACS and workstation are explicitly referenced as a result destination.

exact submission · checked 2026-09-01

Confirm supported products, versions, routing behavior, and display requirements during local evaluation.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for HealthICH; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K190424
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Anatomy
Head/brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-09
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2019-06-13
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
26Fields reviewed
9Source classes checked
1Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 1 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K190424 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-09 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K190424: HealthICH

    U.S. Food and Drug Administration - Published 2019-06-13 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. HealthICH model card (K190424)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K190424

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

Research history

  1. K190424 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K233247

Heuron ICH

Heuron Co., Ltd.

Authorized purpose: Triage and notification of suspected intracranial hemorrhage on non-contrast head CT in adults and transitional adolescents aged 18 years and older, to assist prioritization while full images remain subject to standard-of-care interpretation.

Modality
CT/CTA
Anatomy
Head/brain
Decision
2024-05-15
FDA-cleared K261317

BriefCase-Triage

Aidoc Medical, Ltd.

Authorized purpose: Adult head CTA or mCTA triage for suspected complete large-vessel and medium-vessel occlusion.

Modality
CT/CTA
Anatomy
Head/Brain
Decision
2026-05-14
FDA-cleared K252421

JLK-NCCT

JLK, Inc.

Authorized purpose: Notification-only triage of adult non-contrast head CT for suspected intracranial hemorrhage and large-vessel occlusion, with parallel communication to trained clinicians during standard care.

Modality
CT/CTA
Anatomy
Brain and intracranial vessels: intracranial hemorrhage and LVO involving ICA, MCA-M1, and MCA-M2
Decision
2026-03-24

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history